{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:02:49Z","timestamp":1760547769770},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[1990,12,1]],"date-time":"1990-12-01T00:00:00Z","timestamp":660009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":9132,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[1990,12]]},"DOI":"10.1111\/1523-1747.ep12875174","type":"journal-article","created":{"date-parts":[[2004,7,15]],"date-time":"2004-07-15T05:47:34Z","timestamp":1089870454000},"page":"S161-S165","source":"Crossref","is-referenced-by-count":29,"special_numbering":"S","title":["Long-Term Follow-Up of 120 Patients with AIDS-Related Kaposi's Sarcoma Treated with Interferon Alpha-2A"],"prefix":"10.1016","volume":"95","author":[{"given":"Willy","family":"Rozenbaum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahin","family":"Gharakhanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Sol","family":"Navarette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rima","family":"De Sahb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Cardon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Rouzioux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/1523-1747.ep12875174_bb0010","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-198804000-00001","article-title":"AIDS-associated Kaposi's sarcoma: pathogenesis, clinical course and treatment","volume":"2","author":"Krown","year":"1988","journal-title":"Aids"},{"key":"10.1111\/1523-1747.ep12875174_bb0015","doi-asserted-by":"crossref","first-page":"744","DOI":"10.7326\/0003-4819-103-5-744","article-title":"The natural history of Kaposi's Sarcoma in the Acquired Immunodeficiency Syndrome","volume":"103","author":"Safai","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1111\/1523-1747.ep12875174_bb0020","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJM198512263132609","article-title":"Spontaneous regression of Kaposi's Sarcoma in patients with AIDS","volume":"313","author":"Real","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1111\/1523-1747.ep12875174_bb0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0140-6736(85)91542-9","article-title":"Patients with Kaposi's Sarcoma who opt for no treatment","volume":"2","author":"Levy","year":"1985","journal-title":"Lancet"},{"key":"10.1111\/1523-1747.ep12875174_bb0030","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJM198711193172101","article-title":"Survival with the Acquired Immunodeficiency Syndrome","volume":"317","author":"Rothenberg","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1111\/1523-1747.ep12875174_bb0035","first-page":"1281","article-title":"Mortality associated with mode of presentation in the Acquired Immune Deficiency Syndrome","volume":"73","author":"Moss","year":"1984","journal-title":"JNCI"},{"key":"10.1111\/1523-1747.ep12875174_bb0040","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1136\/bmj.292.6537.1727","article-title":"Length of survival of patients with Acquired Immune Deficiency Syndrome in the United Kingdom","volume":"292","author":"Marasca","year":"1986","journal-title":"Br Med J"},{"key":"10.1111\/1523-1747.ep12875174_bb0045","first-page":"26","article-title":"Clinical review of epidemic Kaposi's Sarcoma with focus on treatment modalities","volume":"35","author":"Goodman","year":"1987","journal-title":"Henry Ford Hosp Med J"},{"key":"10.1111\/1523-1747.ep12875174_bb0050","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/0002-9343(87)90445-1","article-title":"Combination chemotherapy of disseminated Kaposi's Sarcoma in patients with the Acquired Immunodeficiency syndrome","volume":"82","author":"Gelmann","year":"1987","journal-title":"Am J Med"},{"key":"10.1111\/1523-1747.ep12875174_bb0055","first-page":"19","article-title":"The role of radiotherapy for epidemic Kaposi's Sarcoma","volume":"14","author":"Hill","year":"1987","journal-title":"Semin Oncol"},{"key":"10.1111\/1523-1747.ep12875174_bb0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0360-3016(87)90257-4","article-title":"Defining the role of radiation therapy in the management of epidemic Kaposi's Sarcoma","volume":"13","author":"Cooper","year":"1987","journal-title":"I J Rad Oncol Biol Phys"},{"key":"10.1111\/1523-1747.ep12875174_bb0065","first-page":"7","article-title":"Pathophysiology and epidemiology of epidemic Kaposi's Sarcoma","volume":"14","author":"Safai","year":"1987","journal-title":"Semin Oncol"},{"key":"10.1111\/1523-1747.ep12875174_bb0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7326\/0003-4819-111-1-41","article-title":"Zidovudine in patients with Human Immunodeficiency Virus infection and Kaposi's Sarcoma","volume":"111","author":"Lane","year":"1989","journal-title":"Ann Int Med"},{"key":"10.1111\/1523-1747.ep12875174_bb0075","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1001\/jama.1987.03390100105034","article-title":"Treatment of patients with Acquired Immunodeficiency Syndrome and associated manifestations","volume":"257","author":"Kaplan","year":"1987","journal-title":"JAMA"},{"key":"10.1111\/1523-1747.ep12875174_bb0080","first-page":"23","article-title":"The role of chemotherapy for epidemic Kaposi's Sarcoma","volume":"14","author":"Volberding","year":"1987","journal-title":"Semin Oncol"},{"key":"10.1111\/1523-1747.ep12875174_bb0085","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1056\/NEJM198806023182208","article-title":"Human Interferon as a therapeutic agent","volume":"318","author":"Merigan","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1111\/1523-1747.ep12875174_bb0090","doi-asserted-by":"crossref","first-page":"80","DOI":"10.7326\/0003-4819-96-1-80","article-title":"Interferon: immunology and clinical significance","volume":"96","author":"Stiehm","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1111\/1523-1747.ep12875174_bb0095","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/1097-0142(19860415)57:8+<1662::AID-CNCR2820571305>3.0.CO;2-Y","article-title":"Kaposi's Sarcoma and the Acquired Immuno Deficiency Syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors","volume":"57","author":"Krown","year":"1986","journal-title":"Cancer"},{"key":"10.1111\/1523-1747.ep12875174_bb0100","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0002-9343(85)90276-1","article-title":"Human lymphoblastoid interferon treatment of Kaposi's Sarcoma in the acquired immune deficiency syndrome","volume":"78","author":"Gelman","year":"1985","journal-title":"Am J Med"},{"key":"10.1111\/1523-1747.ep12875174_bb0105","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/1097-0142(19870201)59:3+<620::AID-CNCR2820591309>3.0.CO;2-5","article-title":"Treatment of Kaposi's Sarcoma with Interferon alfa-2b (Intron A)","volume":"59","author":"Volberding","year":"1987","journal-title":"Cancer"},{"key":"10.1111\/1523-1747.ep12875174_bb0110","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(88)90810-0","article-title":"Clinical and virorological effects of high dose recombinant interferon alpha in disseminated AIDS. Related Kaposi's Sarcoma","volume":"2","author":"De Wit","year":"1988","journal-title":"Lancet"},{"key":"10.1111\/1523-1747.ep12875174_bb0115","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0140-6736(88)90811-2","article-title":"Anti-retroviral effects of interferon alpha in AIDS-associated Kaposi's Sarcoma","volume":"2","author":"Clifford-Lane","year":"1988","journal-title":"Lancet"},{"key":"10.1111\/1523-1747.ep12875174_bb0120","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/1097-0142(19860415)57:8+<1657::AID-CNCR2820571304>3.0.CO;2-N","article-title":"Heterogeneity of epidemic Kaposi's Sarcoma","volume":"57","author":"Mitsuyasu","year":"1986","journal-title":"Cancer"},{"key":"10.1111\/1523-1747.ep12875174_bb0125","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.V67.3.666.666","article-title":"A prognostically significant classification of immune changes in AIDS with Kaposi's Sarcoma","volume":"67","author":"Taylor","year":"1986","journal-title":"Blood"},{"key":"10.1111\/1523-1747.ep12875174_bb0130","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/1523-1747.ep12461398","article-title":"Disseminated Kaposi's Sarcoma in AIDS: histogenesis-related populations an influence of long-term treatment with rINF-alpha A","volume":"89","author":"Silva","year":"1987","journal-title":"J Invest Dermatol"},{"key":"10.1111\/1523-1747.ep12875174_bb0135","first-page":"417","article-title":"Immunological variables as predictors of prognosis in patients with Kaposi's Sarcoma and the Acquired Immunodeficiency Syndrome","volume":"46","author":"Vadhan-Raj","year":"1986","journal-title":"Cancer Res"},{"key":"10.1111\/1523-1747.ep12875174_bb0140","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(86)91436-4","article-title":"Kaposi's Sarcoma: a reversible hyperplasia","volume":"1","author":"Brooks","year":"1986","journal-title":"Lancet"},{"key":"10.1111\/1523-1747.ep12875174_bb0145","doi-asserted-by":"crossref","first-page":"617","DOI":"10.7326\/0003-4819-100-5-671","article-title":"Recombinant Alpha Interferon therapy for Kaposi's Sarcoma associated with the Acquired Immunodeficiency Syndrome","volume":"100","author":"Groopman","year":"1984","journal-title":"Ann Int Med"},{"key":"10.1111\/1523-1747.ep12875174_bb0150","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.1986.4.4.544","article-title":"Kaposi's Sarcoma and the Acquired Immunodeficiency Syndrome: treatment with high and low doses of recombinant leukocyte A interferon","volume":"4","author":"Real","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1111\/1523-1747.ep12875174_bb0155","first-page":"531","article-title":"Kaposi's Sarcoma: a new staging classification","volume":"67","author":"Krigel","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"10.1111\/1523-1747.ep12875174_bb0160","first-page":"13","article-title":"Clinical variants and staging of Kaposi's Sarcoma","volume":"14","author":"Mitsuyasu","year":"1987","journal-title":"Semin Oncol"},{"key":"10.1111\/1523-1747.ep12875174_bb0165","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/1097-0142(19870201)59:3+<633::AID-CNCR2820591311>3.0.CO;2-I","article-title":"Biology and therapy of epidemic Kaposi's Sarcoma","volume":"59","author":"Groopman","year":"1987","journal-title":"Cancer"},{"key":"10.1111\/1523-1747.ep12875174_bb0170","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0025-7125(16)30945-2","article-title":"Kaposi's Sarcoma and the Acquired Immunodeficiency Syndrome","volume":"70","author":"Volberding","year":"1986","journal-title":"Med Clin North Am"},{"key":"10.1111\/1523-1747.ep12875174_bb0175","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.1989.7.9.1201","article-title":"Kaposi's Sarcoma in the Acquired Immune Deficiency Syndrome: a proposal for uniform evaluation, response, and staging criteria","volume":"7","author":"Krown","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1111\/1523-1747.ep12875174_bb0180","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1099\/0022-1317-42-3-467","article-title":"Effect of Interferon on murine leukemia virus infection. IV formation of non infectious virus in chronically infected cells","volume":"42","author":"Pitha","year":"1979","journal-title":"J Gen Virol"},{"key":"10.1111\/1523-1747.ep12875174_bb0185","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0140-6736(85)92144-0","article-title":"Recombinant human interferon alpha A, suppresses HTVL III replication in vitro","volume":"1","author":"Ho","year":"1985","journal-title":"Lancet"},{"key":"10.1111\/1523-1747.ep12875174_bb0190","first-page":"353","article-title":"The antitumour effect of Interferon","author":"Pitha Rowe","year":"1983"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X9091213U?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X9091213U?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T19:02:26Z","timestamp":1585854146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X9091213U"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1990,12]]}},"alternative-id":["S0022202X9091213U"],"URL":"https:\/\/doi.org\/10.1111\/1523-1747.ep12875174","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[1990,12]]}}}